VYNE Therapeutics Inc (NASDAQ: VYNE) on Friday, plunged -23.94% from the previous trading day, before settling in for the closing price of $1.88. Within the past 52 weeks, VYNE’s price has moved between $1.44 and $4.30.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 900.31% over the last five years. The company achieved an average annual earnings per share of -32.78%. With a float of $12.68 million, this company’s outstanding shares have now reached $14.83 million.
The firm has a total of 13 workers. Let’s measure their productivity. In terms of profitability, gross margin is 100.0%, operating margin of -8709.98%, and the pretax margin is -7944.71%.
VYNE Therapeutics Inc (VYNE) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of VYNE Therapeutics Inc is 16.66%, while institutional ownership is 47.99%. The most recent insider transaction that took place on Jan 15 ’25, was worth 43,800. In this transaction Director of this company bought 15,000 shares at a rate of $2.92, taking the stock ownership to the 51,472 shares.
VYNE Therapeutics Inc (VYNE) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -32.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.50% during the next five years compared to 65.87% growth over the previous five years of trading.
VYNE Therapeutics Inc (NASDAQ: VYNE) Trading Performance Indicators
VYNE Therapeutics Inc (VYNE) is currently performing well based on its current performance indicators. A quick ratio of 4.35 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 43.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.93, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.03 in one year’s time.
Technical Analysis of VYNE Therapeutics Inc (VYNE)
Analysing the last 5-days average volume posted by the [VYNE Therapeutics Inc, VYNE], we can find that recorded value of 0.41 million was better than the volume posted last year of 0.15 million. As of the previous 9 days, the stock’s Stochastic %D was 57.58%. Additionally, its Average True Range was 0.20.
During the past 100 days, VYNE Therapeutics Inc’s (VYNE) raw stochastic average was set at 4.97%, which indicates a significant decrease from 21.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 140.49% in the past 14 days, which was higher than the 91.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9731, while its 200-day Moving Average is $2.2763. Now, the first resistance to watch is $1.5267. This is followed by the second major resistance level at $1.6233. The third major resistance level sits at $1.7467. If the price goes on to break the first support level at $1.3067, it is likely to go to the next support level at $1.1833. Should the price break the second support level, the third support level stands at $1.0867.
VYNE Therapeutics Inc (NASDAQ: VYNE) Key Stats
Market capitalization of the company is 21.75 million based on 15,210K outstanding shares. Right now, sales total 500 K and income totals -39,830 K. The company made 80 K in profit during its latest quarter, and -12,020 K in sales during its previous quarter.
